Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 4.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an S-1 registration filed Jan 23, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$5.7MCash on Hand
4.7mo Cash Runway
Follow AKTX by emailGet an email when AKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AKTX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results with $5.7 million in cash and $4.7 million in operating expenses, versus $7.4 million a year earlier. Initiated GLP toxicology studies for lead ADC AKTX-101, targeting a Phase 1 start in mid-2027 subject to financing. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Shareholder vote Shareholders voted at a special general meeting on October 28, 2026 on an ordinary resolution to increase shares available under the 2023 Plan by 144,000,000,000 ordinary shares (1,800,000 ADSs). The resolution received 79,142,490,228 for, 1,314,720,000 against and 22,005,228 abstentions. Form 8-K · SEC filing
Oct 1, 2026 ·
Leadership CEO Abizer Gaslightwala's base salary rises from $475,000 to $625,000 effective August 18, 2026, with 10% paid in RSUs and target bonus raised from 50% to 55% of salary. He was also granted options on 174,000 ADSs, subject to shareholder approval of a plan amendment. Form 8-K · SEC filing
Oct 1, 2026 ·
Shareholder vote Akari will hold a general meeting on October 28, 2026 for shareholders to vote on increasing the share reserve under its 2023 Equity Incentive Plan by 144,000,000,000 ordinary shares, to 163,806,000,000 ordinary shares. The board unanimously recommends a vote FOR. Form DEF 14A · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 net loss of $4.8 million versus $1.9 million a year earlier, with R&D rising to $2.1 million from $0.7 million. Raised about $8.6 million gross in the quarter, and cash was $7.7 million at June 30, 2026. AKTX-101 Phase 1 start is targeted for mid-2027. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2020 · Phase 3 · Results Expected · Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 Registry primary completion date, not a results date
Mar 2020 · Phase 2 · Results Expected · rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects Registry primary completion date, not a results date
Nov 2018 · Phase 2 · Results Expected · Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Registry primary completion date, not a results date
Mar 2018 · Phase 2 · Results Expected · Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AKTX holds $5.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.7M/quarter from operations,
an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:85 · High
Cash runway 5 months +40
Shelf registration (S-3, Jul 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements.10-Q, Nov 2026
Share count 155,758,529,533 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AKTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.